Indaptus Therapeutics, Inc. Share-based Payment Arrangement, Expense
Indaptus Therapeutics, Inc. (INDP) reported Share-based Payment Arrangement, Expense of $831.18 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2022-05-12
- Indaptus Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2022-03-31 was $831.18K, a 3965.46% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2021-12-31 was $673.80K, a 2818.41% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2021-09-30 was $795.34K, a 1928.51% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2021-06-30 was $124.00K, a 70.05% decline year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2021 was $1.51M, a 979.06% increase from fiscal 2020.
- Indaptus Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2020 was $139.96K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $831.18K 10-Q · filed 2022-05-12 | $1.50M derived: sum of 2 quarters · filed 2022-05-12 | $2.30M derived: sum of 3 quarters · filed 2022-05-12 | $2.42M derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | $673.80K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.47M derived: sum of 2 quarters · filed 2022-03-21 | $1.59M derived: sum of 3 quarters · filed 2022-03-21 | $1.51M 10-K · filed 2022-03-21 |
| 2021-09-30 | $795.34K 10-Q · filed 2021-11-15 | $919.34K derived: sum of 2 quarters · filed 2021-11-15 | $836.46K 10-Q · filed 2021-11-15 | $962.87K derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | $124.00K 10-Q · filed 2021-08-16 | $208.00K 10-Q · filed 2021-08-16 | $167.53K derived: sum of 3 quarters · filed 2022-05-12 | $206.74K derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | $20.45K 10-Q · filed 2022-05-12 | $43.53K derived: sum of 2 quarters · filed 2022-05-12 | $82.74K derived: sum of 3 quarters · filed 2022-05-12 | $496.74K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $23.09K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $62.30K derived: sum of 2 quarters · filed 2022-03-21 | $476.30K derived: sum of 3 quarters · filed 2022-03-21 | $139.96K 10-K · filed 2022-03-21 |
| 2020-09-30 | $39.21K 10-Q · filed 2021-11-15 | $453.21K derived: sum of 2 quarters · filed 2021-11-15 | $116.87K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $414.00K 10-Q · filed 2021-08-16 | $856.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |